BR112013003101A2 - inibidores do vírus da hepatite c - Google Patents

inibidores do vírus da hepatite c

Info

Publication number
BR112013003101A2
BR112013003101A2 BR112013003101A BR112013003101A BR112013003101A2 BR 112013003101 A2 BR112013003101 A2 BR 112013003101A2 BR 112013003101 A BR112013003101 A BR 112013003101A BR 112013003101 A BR112013003101 A BR 112013003101A BR 112013003101 A2 BR112013003101 A2 BR 112013003101A2
Authority
BR
Brazil
Prior art keywords
hepatitis
compounds
virus inhibitors
virus
treatment
Prior art date
Application number
BR112013003101A
Other languages
English (en)
Portuguese (pt)
Inventor
John A Bender
Makonen Belema
Nicholas A Meanwell
Omar D Lopez
Pothukanuri Srinivasu
Qi Chen
Richard A Rampulla
Samayamunthula Venkata Satya Arun Kumar Gupta
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112013003101A2 publication Critical patent/BR112013003101A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112013003101A 2010-08-12 2011-08-10 inibidores do vírus da hepatite c BR112013003101A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37307010P 2010-08-12 2010-08-12
US13/198,529 US20120195857A1 (en) 2010-08-12 2011-08-04 Hepatitis C Virus Inhibitors
PCT/US2011/047211 WO2012021591A1 (en) 2010-08-12 2011-08-10 Hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
BR112013003101A2 true BR112013003101A2 (pt) 2016-06-28

Family

ID=44534668

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013003101A BR112013003101A2 (pt) 2010-08-12 2011-08-10 inibidores do vírus da hepatite c

Country Status (11)

Country Link
US (1) US20120195857A1 (https=)
EP (1) EP2603504A1 (https=)
JP (1) JP5805763B2 (https=)
CN (1) CN103249731A (https=)
AR (1) AR082681A1 (https=)
BR (1) BR112013003101A2 (https=)
CA (1) CA2808061A1 (https=)
EA (1) EA024171B1 (https=)
MX (1) MX2013001579A (https=)
TW (1) TW201211032A (https=)
WO (1) WO2012021591A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
IN2012DN00999A (https=) 2009-07-16 2015-04-10 Vertex Pharma
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2794145A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
BR112013004520A2 (pt) 2010-08-26 2016-06-07 Univ Emory inibidores potentes e seletivos do virus da hepatite c
EP2651928A4 (en) * 2010-12-15 2014-06-18 Abbvie Inc ANTI-VIRAL COMPOUNDS
US8552047B2 (en) * 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112013022552B1 (pt) 2011-03-04 2021-11-23 Newgen Therapeutics, Inc Compostos de quinazolina substituídos com alcino, seu uso, composição farmacêutica, e kit
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US9303061B2 (en) 2011-07-09 2016-04-05 Sunshine Luke Pharma Co., Ltd. Spiro compounds as Hepatitis C virus inhibitors
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
CN103946220B (zh) 2011-11-03 2017-12-22 施万生物制药研发Ip有限责任公司 含有片段{2‑[4‑(联苯‑4‑基)‑1h‑咪唑‑2‑基]吡咯烷‑1‑羰基甲基}胺的杆状丙型肝炎病毒抑制剂
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2862755A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
HUE032173T2 (en) 2012-04-25 2017-09-28 Theravance Biopharma R&D Ip Llc Piperazine piperidine compounds as inhibitors of hepatitis C virus
MX2014013489A (es) * 2012-05-09 2015-02-12 Bayer Cropscience Ag 5-halogenopirazolindanil carboxamidas.
CN103420991B (zh) * 2012-05-17 2017-07-07 乳源东阳光药业有限公司 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
TW201412709A (zh) * 2012-09-28 2014-04-01 Sunshine Lake Pharma Co Ltd 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用
US9802949B2 (en) 2012-11-29 2017-10-31 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
CN103848819B (zh) * 2012-11-29 2017-04-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们在药物中的应用
US9416139B2 (en) 2012-11-29 2016-08-16 Sunshine Lake Pharma Co., Ltd. Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
JP6306874B2 (ja) * 2013-12-20 2018-04-04 住友化学株式会社 臭素化合物の製造方法
CN104803989B (zh) * 2014-01-23 2017-12-22 广东东阳光药业有限公司 作为丙型肝炎抑制剂的桥环化合物及其在药物中的应用
CN105085493A (zh) * 2014-04-15 2015-11-25 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用
CN105272972B (zh) * 2014-05-30 2018-12-11 上海唐润医药科技有限公司 具有抗病毒活性的苯并杂环己二烯衍生物
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
NZ726343A (en) * 2014-06-12 2018-04-27 Gilead Sciences Inc Antiviral compounds
TWI675029B (zh) * 2014-12-16 2019-10-21 大陸商廣東東陽光藥業有限公司 作為丙型肝炎抑制劑的橋環化合物及其製備方法
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2017076201A1 (zh) * 2015-11-06 2017-05-11 江苏豪森药业集团有限公司 Hcv抑制剂、其制备方法与应用
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
KR20230031990A (ko) 2018-02-28 2023-03-07 노파르티스 아게 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물
WO2020112357A1 (en) * 2018-11-28 2020-06-04 The Regents Of The University Of Michigan Succinate dehydrogenase inhibitors and methods of making and using the same
JP2025525344A (ja) 2022-06-21 2025-08-05 アストラゼネカ・アクチエボラーグ Ｎ－（２－（４－シアノチアゾリジン－３－イル）－２－オキソエチル）－キノリン－４－カルボキサミド

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014852A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
DE102004036971B4 (de) 2004-07-30 2009-07-30 Advanced Micro Devices, Inc., Sunnyvale Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7728027B2 (en) * 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
ATE551337T1 (de) * 2008-02-12 2012-04-15 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SI2373172T1 (sl) * 2008-12-03 2013-12-31 Presidio Pharmaceuticals, Inc. Inhibitorji HCV NS5A
PT3309157T (pt) * 2009-05-13 2019-12-02 Gilead Pharmasset Llc Compostos antivirais
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN104530079B (zh) * 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂

Also Published As

Publication number Publication date
EA201390190A1 (ru) 2013-06-28
JP2013533317A (ja) 2013-08-22
EA024171B1 (ru) 2016-08-31
US20120195857A1 (en) 2012-08-02
MX2013001579A (es) 2013-05-22
WO2012021591A1 (en) 2012-02-16
CN103249731A (zh) 2013-08-14
JP5805763B2 (ja) 2015-11-04
AR082681A1 (es) 2012-12-26
TW201211032A (en) 2012-03-16
CA2808061A1 (en) 2012-02-16
EP2603504A1 (en) 2013-06-19

Similar Documents

Publication Publication Date Title
BR112013003101A2 (pt) inibidores do vírus da hepatite c
BR112013002729A2 (pt) inibidores de vírus de hepatite c
BR112012011100A2 (pt) compostos inibidores do vírus da hepatite, composição e uso dos mesmos
BR112012014677A2 (pt) inibidores do vírus da hepatite c
BR112013028679A2 (pt) inibidores do vírus da hepatite c
BR112013020042A2 (pt) inibidores de vírus da hepatite c
EA200900297A1 (ru) Ингибиторы вируса гепатита с
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
MY152971A (en) Hepatitis c virus inhibitors
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
MX2010008531A (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
DK2250163T3 (da) Hepatitis C-virusinhibitorer
EA200900298A1 (ru) Ингибиторы вируса гепатита с
BR112014008616A2 (pt) compostos antivirais
MX354676B (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).
TN2013000335A1 (en) Hepatitis c virus inhibitors
TN2013000453A1 (en) Hepatitis c virus inhibitors
TH149188A (th) สารยับยั้งไวรัสตับอักเสบ c
CO6290680A2 (es) Inhibidores de virus de la hepatitis c
CY1114249T1 (el) Αναστολεις του ιου ηπατιτιδας c
CL2012001269A1 (es) Compuestos derivados de bi-imidazol di-sustituidos; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar infecciones por virus de hepatitis c (vhc).

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2474 DE 05-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.